SCHEMBL4123420

SCHEMBL4123420

CCOC(=O)c1c(O)c(-c2ccsc2)nn(Cc2ccc(F)cc2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
ADORA1 P30542 2/20 0.43
CDC7 O00311 1/20 0.43
DBF4 Q9UBU7 1/20 0.43
MAPT P10636 2/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 2/20 0.41
PKM P14618 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40
FEN1 P39748 2/20 0.39
PRKCZ Q05513 1/20 0.39
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3850103 0.84 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DADORA1
SCHEMBL14006532 0.83 ALDH1A1 (0.42) PDE4APDE4BPDE4CPDE4DADORA1
SCHEMBL3845552 0.79 MET (0.45) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL3851363 0.78 PDE4A (0.61) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4137219 0.78 ADORA1 (0.45) ADORA1MEN1KMT2AHSD17B10KDM4E
SCHEMBL3852292 0.78 KDM4E (0.45) MAPTTRPM8MEN1KMT2AKDM4E
SCHEMBL4136431 0.77 CNR2 (0.54)
SCHEMBL3849543 0.77 ALDH1A1 (0.47) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL3845820 0.77 EGLN3 (0.61) PDE4APDE4BPDE4CPDE4DADORA1
SCHEMBL3847510 0.75 EGLN3 (0.55) PDE4APDE4BPDE4CPDE4DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060867-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI POLR2E, POLR2H, POLI PDE4A 893/4885PDE4B 1374/4885PDE4C 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.